IP Library Granted Patent US 8,759,026
Granted Patent B2
US 8,759,026 · App. 13/622,939 · Granted Jun 24, 2014

Methods for increasing recovery of an ADAMTS activity from a cell culture supernatant

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,759,026
App. No.
13/622,939
Granted
Jun 24, 2014
Kind
B2
Abstract

The present invention provides culture mediums that are useful for the expression of ADAMTS proteins, such as ADAMTS13. Methods for the expression and purification of ADAMTS proteins are also provided. In some embodiments, the mediums and methods of the invention are useful for the expression of ADAMTS proteins having high specific activities. Also provided are ADAMTS, e.g., ADAMTS13, protein compositions with high specific activities, which are expressed and purified according to the methods provided herein.

Claims (37)

1. A method for increasing recovery of an ADAMTS activity from a cell culture supernatant, the method comprising the steps of:

(a) culturing a cell harboring a nucleic acid encoding an ADAMTS protein in a culture medium;

(b) removing a fraction of the supernatant from the culture;

(c) performing a filtration or centrifugation step to remove residual cells from the fraction of the supernatant removed from the culture, thereby forming a clarified supernatant;

(d) concentrating ADAMTS protein in the clarified supernatant by ultrafiltration, thereby forming a concentrated supernatant; and

(e) diafiltering the concentrated supernatant against a buffer comprising at least about 0.5 μM zinc and at least about 0.1 mM calcium; thereby preparing an ADAMTS composition with increased recovery of ADAMTS activity.

2. The method of claim 1 , wherein the step of culturing a cell comprises batch cell cultivation.

3. The method of claim 1 , wherein the step of culturing a cell comprises continuous cell cultivation.

4. The method of claim 1 , wherein the culture medium comprises at least 3 μM zinc and at least 0.5 mM calcium.

5. The method of claim 4 , wherein the culture medium comprises at least 5 μM zinc.

6. The method of claim 4 , wherein the culture medium contains at least 2 mg/L nicotinamide (vitamin B3).

7. The method of claim 4 , wherein the culture medium contains at least 7 mg/L nicotinamide (vitamin B3).

8. The method of claim 5 , wherein the culture medium contains at least 2 mg/L nicotinamide (vitamin B3).

9. The method of claim 5 , wherein the culture medium contains at least 7 mg/L nicotinamide (vitamin B3).

10. The method of claim 1 , wherein the diafiltration buffer contains at least 5 μM zinc and at least 2 mM calcium.

11. The method of claim 4 , wherein the diafiltration buffer contains at least 5 μM zinc and at least 2 mM calcium.

12. The method of claim 7 , wherein the diafiltration buffer contains at least 5 μM zinc and at least 2 mM calcium.

13. The method of claim 1 , wherein the ADAMTS protein in is ADAMTS13.

14. The method of claim 4 , wherein the ADAMTS protein is ADAMTS13.

15. The method of claim 7 , wherein the ADAMTS protein is ADAMTS13.

16. The method of claim 10 , wherein the ADAMTS protein is ADAMTS13.

17. The method of claim 11 , wherein the ADAMTS protein is ADAMTS13.

18. The method of claim 12 , wherein the ADAMTS protein is ADAMTS13.

19. The method of claim 13 , wherein the ADAMTS13 specific activity of the composition formed in step (e) is at least 80% of the ADAMTS13 specific activity of the clarified supernatant formed in step (c).

20. The method of claim 5 , wherein the culture medium contains from 5 μM to 12 μM zinc.

21. The method of claim 6 , wherein the culture medium contains from 5 μM to 12 μM zinc.

22. The method of claim 7 , wherein the culture medium contains from 5 μM to 12 μM zinc.

23. The method of claim 8 , wherein the culture medium contains from 5 μM to 12 μM zinc.

24. The method of claim 9 , wherein the culture medium contains from 5 μM to 12 μM zinc.

25. The method of claim 10 , wherein the culture medium contains from 5 μM to 12 μM zinc.

26. The method of claim 12 , wherein the culture medium contains from 5 μM to 12 μM zinc.

27. The method of claim 13 , wherein the culture medium contains from 5 μM to 12 μM zinc.

28. The method of claim 15 , wherein the culture medium contains from 5 μM to 12 μM zinc.

29. The method of claim 16 , wherein the culture medium contains from 5 μM to 12 μM zinc.

30. The method of claim 18 , wherein the culture medium contains from 5 μM to 12 μM zinc.

31. The method of claim 6 , wherein the culture medium contains from 2 mg/L to 10 mg/L nicotinamide (vitamin B3).

32. The method of claim 8 , wherein the culture medium contains from 2 mg/L to 10 mg/L nicotinamide (vitamin B3).

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 31, 2021
From: BAXALTA GMBH; BAXALTA INCORPORATED
To: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Reel/Frame 055188/0953 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 17, 2015
From: BAXTER INTERNATIONAL INC.
To: BAXALTA GMBH; BAXALTA INCORPORATED
Reel/Frame 036372/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 17, 2015
From: BAXTER HEALTHCARE SA
To: BAXALTA GMBH; BAXALTA INCORPORATED
Reel/Frame 036376/0572 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 23, 2013
From: GRILLBERGER, LEOPOLD; SPENGER, ALEXANDRA; HASSLACHER, MEINHARD; GRILLBERGER, RANA; REITER, MANFRED
To: BAXTER INTERNATIONAL INC.; BAXTER HEALTHCARE S.A.
Reel/Frame 030265/0419 →